biomonitoring of ochratoxin a and its metabolite ochratoxin alpha in urine, plasma and human milk

1
Abstracts / Toxicology Letters 189S (2009) S57–S273 S151 Y02 1,N 2 -propanodeoxyguanosine adducts of 4-hydroxy-2-nonenals as highly specific markers for cancer risk from oxidative stress and lipid peroxidation Erwin Eder , Paul Wanek, Ellen Biskup University of Würzburg, Toxicology, Würzburg, Germany 1,N 2 -propanodeoxyguanine adducts (dG) of the most prominent lipid peroxidation product 4-hydroxy-2-nonenal (HNE), (HNE-dG) are highly specific DNA adducts for cancer risk induced by lipid peroxidation and oxidative stress because the adduct molecule contains the complete structural moiety of HNE and can exclu- sively be formed by HNE in contrast to ethenoadducts which can be also formed by a series of other compounds. HNE-dG is rel- atively stable, is repaired only by nucleotide excision repair and not by base excision repair like ethenoadducts, and is associated with mutations in hotspots of tumour suppressor genes and pro- tooncogenes. HNE-dG can lead to initiation of tumour cells and to tumour progression in the course of the multiple stage concept of carcinogenesis. Therefore, HNE-dG is an excellent marker for cancer risk induced by oxidative stress and lipid peroxidation. Oxidative stress and lipid peroxidation play a major role in carcinogenesis and are triggered by several physiological and pathophysiological processes in our cells, e.g. in mitochondrial breathing, inflammation induced by infections, metal storage disorders like hemochromato- sis or Wilson’s disease etc. Most chemopreventive mechanisms work via oppression of oxidative stress and lipid peroxidation. Thus HNE-dG adduct levels can be reliably used as markers for cancer risk induced by biological processes leading to lipid perox- idation or conversely to investigate chemopreventive interactions and potencies. We have developed a postlabelling technique to reli- ably measure HNE-dG with a sensitivity of two adducts per 10 9 nucleotides. We also have shown that our method can be used in a large intervention study in humans. Selected for Oral Presentation. doi:10.1016/j.toxlet.2009.06.745 Y03 MicroRNA Biomarkers for Carcinogen Exposure in Rodents Tao Chen National Center for Toxicological Research, US FDA, Divison of Genetic and Reproductive Toxicology, Jefferson, United States MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression and control cellular mechanisms. Dys- regulated expression of miRNAs has been extensively detected in human cancers and has shown promise in defining tumor status. It, however, is little known whether expression of miRNAs can be changed in non-carncerous tissures after carcinogen exprosure. To investigate the potential miRNA biomarkers for chemical car- cinogen exposue, we determined miRNA expression profiles using microarray and PCR array from tissues of mice and rats treated with different carcinogens. A number of miRNAs in the tumor target tissues were significantly dysregulated by carcinogen treat- ments while there were only a few of miRNAs whose expressions were changed in the non-target tissues or samples treated with non-carcinogen chemicals. Most of these miRNAs altered by the carcinogen exposures were involved in cancer-related functions like DNA repair, cell apoptosis and cell growth. Our time-course study using one dose treatment of N-ethyl-N-nitrosourea indicated that miRNAs could be changed in one day after the treatment and the number of differentially expressed miRNAs reached a peck one week after the exposure. Our results suggest that most of the differential expressed miRNAs are oncogenic miRNAs in the tumoric target tissues and the alteration of their expressions may be early indicators of carcinogenic insulation. Thus, these miRNAs can become potential biomarkers for exposure of carcinogens. doi:10.1016/j.toxlet.2009.06.746 Y04 Biomonitoring of Ochratoxin A and its metabolite Ochratoxin alpha in urine, plasma and human milk Katherine Munoz 1,, Gisela Degen 1 , Meinolf Blaszkewicz 1 , Victor Campos 2 , Jorge Neira 3 , Mario Vega 2 1 Leibniz-Institute für Arbeitsforschung an der TU Dortmund, Dortmund, Germany, 2 University of Concepcion, Department of Food Science, Concepcion, Chile, 3 University of Concepcion, Department of Paediatrics, Concepcion, Chile Ochratoxin A (OTA) is a mycotoxin contaminant found worldwide in foods and feeds. Biomonitoring can be applied to assess OTA exposure from dietary mycotoxin intake and other sources. OTA levels in human blood and/or urine provide good estimates of past and recent exposure. But, measuring OTA alone does not reflect its biotransformation in the organism, and presently information on OTA metabolites in humans is scarce. Thus, we have developed an improved method that allows both detection of OTA and its major metabolite Ochratoxin alpha (OT) in plasma, urine and breast milk. Method: The method involves liquid–liquid extraction with chloroform and subsequent analysis by HPLC with fluorescence detection, and it has been validated for all matrices. Results: In a pilot study with non-lactating women who pro- vided blood and urine samples on the same day, OTA and OT were detected in all samples: whilst OTA is the predominant form in plasma (mean 0.24 ng/ml) its level is much lower in urine (0.05 ng/ml). Conversely, OT is the predominant metabolite in urine (mean 1 ng/ml), and also detectable in serum (0.1 ng/ml). Conclusion: This data implies that measuring OTA (parent compound) alone may underestimate mycotoxin exposure when metabolites are not analyzed in parallel, and that biomonitoring, especially in urine samples, is improved by including OT. Analysis of human breast milk samples is currently underway to shed some light on the transfer of OTA (and OT) in lactating mothers. KM receives stipends from DAAD and CONICYT. doi:10.1016/j.toxlet.2009.06.747 Y05 Perfluorinated compounds (PFC) in human breast milk Wolfgang Völkel , Christine Mosch, Mandy Kiranoglu, Ulla Verdugo-Raab, Hermann Fromme LGL-Bayern, Environmental Medicine, München, Germany Perfluorinated compounds (PFC) are a large group of chemicals pro- duced for several decades and widely used for many industrial and consumer applications. Due to their global distribution, their per-

Upload: katherine-munoz

Post on 30-Nov-2016

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Biomonitoring of Ochratoxin A and its metabolite Ochratoxin alpha in urine, plasma and human milk

Abstracts / Toxicology Letters 189S (2009) S57–S273 S151

Y021,N2-propanodeoxyguanosine adducts of 4-hydroxy-2-nonenalsas highly specific markers for cancer risk from oxidative stress

and lipid peroxidation�

Erwin Eder ∗, Paul Wanek, Ellen Biskup

University of Würzburg, Toxicology, Würzburg, Germany

1,N2-propanodeoxyguanine adducts (dG) of the most prominentlipid peroxidation product 4-hydroxy-2-nonenal (HNE), (HNE-dG)are highly specific DNA adducts for cancer risk induced by lipidperoxidation and oxidative stress because the adduct moleculecontains the complete structural moiety of HNE and can exclu-sively be formed by HNE in contrast to ethenoadducts which canbe also formed by a series of other compounds. HNE-dG is rel-atively stable, is repaired only by nucleotide excision repair andnot by base excision repair like ethenoadducts, and is associatedwith mutations in hotspots of tumour suppressor genes and pro-tooncogenes. HNE-dG can lead to initiation of tumour cells and totumour progression in the course of the multiple stage concept ofcarcinogenesis. Therefore, HNE-dG is an excellent marker for cancerrisk induced by oxidative stress and lipid peroxidation. Oxidativestress and lipid peroxidation play a major role in carcinogenesisand are triggered by several physiological and pathophysiologicalprocesses in our cells, e.g. in mitochondrial breathing, inflammationinduced by infections, metal storage disorders like hemochromato-sis or Wilson’s disease etc. Most chemopreventive mechanismswork via oppression of oxidative stress and lipid peroxidation.Thus HNE-dG adduct levels can be reliably used as markers forcancer risk induced by biological processes leading to lipid perox-idation or conversely to investigate chemopreventive interactionsand potencies. We have developed a postlabelling technique to reli-ably measure HNE-dG with a sensitivity of two adducts per 109

nucleotides. We also have shown that our method can be used in alarge intervention study in humans.

� Selected for Oral Presentation.

doi:10.1016/j.toxlet.2009.06.745

Y03MicroRNA Biomarkers for Carcinogen Exposure in Rodents

Tao Chen

National Center for Toxicological Research, US FDA, Divison ofGenetic and Reproductive Toxicology, Jefferson, United States

MicroRNAs (miRNAs) are small non-coding RNAs that negativelyregulate gene expression and control cellular mechanisms. Dys-regulated expression of miRNAs has been extensively detected inhuman cancers and has shown promise in defining tumor status.It, however, is little known whether expression of miRNAs canbe changed in non-carncerous tissures after carcinogen exprosure.To investigate the potential miRNA biomarkers for chemical car-cinogen exposue, we determined miRNA expression profiles usingmicroarray and PCR array from tissues of mice and rats treatedwith different carcinogens. A number of miRNAs in the tumortarget tissues were significantly dysregulated by carcinogen treat-ments while there were only a few of miRNAs whose expressionswere changed in the non-target tissues or samples treated withnon-carcinogen chemicals. Most of these miRNAs altered by thecarcinogen exposures were involved in cancer-related functions

like DNA repair, cell apoptosis and cell growth. Our time-coursestudy using one dose treatment of N-ethyl-N-nitrosourea indicatedthat miRNAs could be changed in one day after the treatment andthe number of differentially expressed miRNAs reached a peckone week after the exposure. Our results suggest that most ofthe differential expressed miRNAs are oncogenic miRNAs in thetumoric target tissues and the alteration of their expressions maybe early indicators of carcinogenic insulation. Thus, these miRNAscan become potential biomarkers for exposure of carcinogens.

doi:10.1016/j.toxlet.2009.06.746

Y04Biomonitoring of Ochratoxin A and its metabolite Ochratoxinalpha in urine, plasma and human milk

Katherine Munoz 1,∗, Gisela Degen 1, Meinolf Blaszkewicz 1,Victor Campos 2, Jorge Neira 3, Mario Vega 2

1 Leibniz-Institute für Arbeitsforschung an der TU Dortmund,Dortmund, Germany, 2 University of Concepcion, Department of FoodScience, Concepcion, Chile, 3 University of Concepcion, Department ofPaediatrics, Concepcion, Chile

Ochratoxin A (OTA) is a mycotoxin contaminant found worldwidein foods and feeds. Biomonitoring can be applied to assess OTAexposure from dietary mycotoxin intake and other sources. OTAlevels in human blood and/or urine provide good estimates of pastand recent exposure. But, measuring OTA alone does not reflect itsbiotransformation in the organism, and presently information onOTA metabolites in humans is scarce. Thus, we have developed animproved method that allows both detection of OTA and its majormetabolite Ochratoxin alpha (OT�) in plasma, urine and breastmilk.

Method: The method involves liquid–liquid extraction withchloroform and subsequent analysis by HPLC with fluorescencedetection, and it has been validated for all matrices.

Results: In a pilot study with non-lactating women who pro-vided blood and urine samples on the same day, OTA and OT�were detected in all samples: whilst OTA is the predominant formin plasma (mean 0.24 ng/ml) its level is much lower in urine(0.05 ng/ml). Conversely, OT� is the predominant metabolite inurine (mean 1 ng/ml), and also detectable in serum (0.1 ng/ml).

Conclusion: This data implies that measuring OTA (parentcompound) alone may underestimate mycotoxin exposure whenmetabolites are not analyzed in parallel, and that biomonitoring,especially in urine samples, is improved by including OT�. Analysisof human breast milk samples is currently underway to shed somelight on the transfer of OTA (and OT�) in lactating mothers.

KM receives stipends from DAAD and CONICYT.

doi:10.1016/j.toxlet.2009.06.747

Y05Perfluorinated compounds (PFC) in human breast milk

Wolfgang Völkel ∗, Christine Mosch, Mandy Kiranoglu, UllaVerdugo-Raab, Hermann Fromme

LGL-Bayern, Environmental Medicine, München, Germany

Perfluorinated compounds (PFC) are a large group of chemicals pro-duced for several decades and widely used for many industrial andconsumer applications. Due to their global distribution, their per-